Literature DB >> 33196429

A Pharmacist-Led Program to Taper Opioid Use at Kaiser Permanente Northwest: Rationale, Design, and Evaluation.

Jennifer L Kuntz1, Jennifer L Schneider1, Alison J Firemark1, John F Dickerson1, Dea Papajorgji-Taylor1, Katherine R Reese2, Traci A Hamer2, Darlene Marsh2, Lou Ann Thorsness2, Mark D Sullivan3, Lynn L Debar4, David H Smith1.   

Abstract

INTRODUCTION: Primary care practitioners (PCPs) are concerned about adverse effects and poor outcomes of opioid use but may find opioid tapering difficult because of a lack of pain management training or time constraints limiting patient counseling. In 2010, Kaiser Permanente Northwest implemented a pharmacist-led opioid tapering program-Support Team Onsite Resource for Management of Pain (STORM)-to address high rates of opioid use, alleviate PCPs' workload demands, and improve patient outcomes.
OBJECTIVE: To describe the rationale, structure, and delivery of this unique pharmacist-led program, which partners with PCPs and provides individualized care to help patients reduce opioid use, and the Facilitating Lower Opioid Amounts through Tapering study, which examines the program's effectiveness, cost-effectiveness, and implementation.
RESULTS: The STORM program includes a pain medicine physician, a social worker or nurse, and pharmacists who have received specialized clinical and communications training. The program has a 2-fold role: 1) to provide PCP education about pain management and opioid use and 2) to offer clinician and patient support with opioid tapering and pain management. After program training, PCPs are equipped to discuss the need for tapering with a patient and to refer to the program. Program pharmacists provide a range of services, including opioid taper plans, nonopioid pain management recommendations, and taper-support outreach to patients. DISCUSSION: The STORM program provides individualized care to assist patients with opioid tapering while reducing the burden on PCPs.
CONCLUSION: The STORM program may be a valuable addition to health care systems and settings seeking options to address their patients' opioid tapering needs.

Entities:  

Year:  2020        PMID: 33196429      PMCID: PMC7213382          DOI: 10.7812/TPP/19.216

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  28 in total

1.  Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective.

Authors:  Laxmaiah Manchikanti; Bert Fellows; Hary Ailinani; Vidyasagar Pampati
Journal:  Pain Physician       Date:  2010 Sep-Oct       Impact factor: 4.965

2.  Coronary artery disease and hypertension: outcomes of a pharmacist-managed blood pressure program.

Authors:  Karen J McConnell; Emily B Zadvorny; Angela M Hardy; Thomas Delate; Jon R Rasmussen; John A Merenich
Journal:  Pharmacotherapy       Date:  2006-09       Impact factor: 4.705

3.  Team-Based Medicine: Incorporating a Clinical Pharmacist into Pain and Opioid Practice Management.

Authors:  Lacey L Boren; Amanda M Locke; Andrew S Friedman; Craig C Blackmore; Roger Woolf
Journal:  PM R       Date:  2019-04-16       Impact factor: 2.298

4.  Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study.

Authors:  Mark J Edlund; Bradley C Martin; Ming-Yu Fan; Andrea Devries; Jennifer B Braden; Mark D Sullivan
Journal:  Drug Alcohol Depend       Date:  2010-07-14       Impact factor: 4.492

5.  High-risk use by patients prescribed opioids for pain and its role in overdose deaths.

Authors:  Jane A Gwira Baumblatt; Caleb Wiedeman; John R Dunn; William Schaffner; Leonard J Paulozzi; Timothy F Jones
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

6.  Opioid prescriptions for chronic pain and overdose: a cohort study.

Authors:  Kate M Dunn; Kathleen W Saunders; Carolyn M Rutter; Caleb J Banta-Green; Joseph O Merrill; Mark D Sullivan; Constance M Weisner; Michael J Silverberg; Cynthia I Campbell; Bruce M Psaty; Michael Von Korff
Journal:  Ann Intern Med       Date:  2010-01-19       Impact factor: 25.391

7.  A randomized, pragmatic, pharmacist-led intervention reduced opioids following orthopedic surgery.

Authors:  David H Smith; Jennifer L Kuntz; Lynn L DeBar; Jill Mesa; Xiuhai Yang; Jennifer Schneider; Amanda Petrik; Katherine Reese; Lou Ann Thorsness; David Boardman; Eric S Johnson
Journal:  Am J Manag Care       Date:  2018-11       Impact factor: 2.229

Review 8.  Opioid analgesia: perspectives on right use and utility.

Authors:  Jane C Ballantyne
Journal:  Pain Physician       Date:  2007-05       Impact factor: 4.965

9.  Expanding the role of clinical pharmacists on interdisciplinary primary care teams for chronic pain and opioid management.

Authors:  Karleen F Giannitrapani; Peter A Glassman; Derek Vang; Jeremiah C McKelvey; R Thomas Day; Steven K Dobscha; Karl A Lorenz
Journal:  BMC Fam Pract       Date:  2018-07-03       Impact factor: 2.497

Review 10.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

View more
  3 in total

Review 1.  Adjunct Digital Interventions Improve Opioid-Based Pain Management: Impact of Virtual Reality and Mobile Applications on Patient-Centered Pharmacy Care.

Authors:  Hayam Y Giravi; Zack Biskupiak; Linda S Tyler; Grzegorz Bulaj
Journal:  Front Digit Health       Date:  2022-06-13

2.  Factors associated with opioid-tapering success: A mixed methods study.

Authors:  Jennifer L Kuntz; John F Dickerson; Jennifer L Schneider; Alison J Firemark; Dea Papajorgji-Taylor; Matthew Slaughter; Katherine R Reese; Lou Ann Thorsness; Mark D Sullivan; Lynn L Debar; David H Smith
Journal:  J Am Pharm Assoc (2003)       Date:  2021-01-21

3.  "We Need to Taper." Interviews with Clinicians and Pharmacists About Use of a Pharmacy-Led Opioid Tapering Program.

Authors:  Alison J Firemark; Jennifer L Schneider; Jennifer L Kuntz; Dea Papajorgji-Taylor; John F Dickerson; Lou Ann Thorsness; Katherine R Reese; Mark D Sullivan; Lynn L Debar; David H Smith
Journal:  Pain Med       Date:  2021-05-21       Impact factor: 3.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.